HLA Protein Technologies provides validated soluble HLA Class I and II molecules, as well as quantitative peptide binding, epitope mapping, immune target validation, and transplant antibody monitoring assay development services for research and therapeutic applications. Visit hlaprotein.com or book a 15-minute technical call to discuss custom projects.

For more than 20 years, we have produced endogenously loaded, mammalian-expressed soluble HLA proteins that maintain physiologically relevant HLA structure and peptide occupancy. These molecules form the foundation of multiple derived assay platforms—including peptide binding and screening assays, T-cell epitope mapping, and antibody binding and monitoring systems—used in oncology, vaccines, transplantation, and translational immunology. 

Our industrialized production delivers 126 Class I and 154 Class II HLA molecules in unmodified and biotinylated formats, supported by lot-traceable QC, standardized SOPs, and assay-transfer–ready workflows.

Derived services and platforms include quantitative peptide-binding (IC₅₀) validation, focused peptide library screening, T-cell epitope mapping, custom HLA–peptide reagent generation, and transplant antibody monitoring platform development, supporting academic laboratories, transplant centers, CROs, and biopharma teams.

Our products and services enable robust target validation, reproducible HLA restriction assignment, reliable assessment of antibody specificity, and accelerated assay development time for immunotherapy, immune monitoring, and transplant applications.

Visit hlaprotein.com or book a 15-minute technical call to discuss custom projects.

HLA Protein Technologies

Org chart

Teams

Offices